Xenotransplantation Market to Register CAGR of 8.52 % until 2031
Increasing demand for tissue and organ
transplantation and rise in organ surgeries are driving the growth of global xenotransplantation
market during the forecast period.
According to TechSci report on, “Xenotransplantation Market - Global Industry Size, Share, Trends, Competition,
Opportunities and Forecast, 2021-2031”, the
global Xenotransplantation market stood at USD 740.24 million in 2021 and is
expected to grow at a CAGR of 8.52% during the forecast period. Transplantation
is an effective treatment option for end-stage organ failure. The supply-demand
imbalance for human organs, on the other hand, is a bottleneck for clinical
transplantation. According to the US Government, Information on Organ Donation
and Transplantation, more than 113,000 people were on the transplant waiting
list in the United States as of January 2019, whereas only 36,528 transplants
were performed in 2018. Since June 2020, living donor transplants have occurred
at a rate more similar in nature to pre-pandemic activity. As a result of the
decline in living donor transplantation, an overall total of 39,034 transplants
from both living and deceased donors were performed in the United States. According
to preliminary data from the United Network for Organ Sharing (UNOS), which
serves as the Organ Procurement and Transplantation Network under federal law,
41,354 organ transplants were performed in the United States in 2021, a 5.9 %
increase over 2020 and the first time the annual total exceeded 40,000. Thus, xenotransplantation will emerge
as an easily available medication without undergoing any difficulty with the
rising surgeries. The increase in the number of organ transplantation due to
rising infectious diseases is also influencing the growth of the global xenotransplantation
market throughout the five years until 2031.
While still in the experimental stages, xenotransplantation is a
potentially life-saving option for people suffering from severe heart disease
and kidney failure. Preliminary results from experiments using transplanted pig
cells in patients with diabetes and Parkinson's disease are promising.
Browse over 122 market
data Figures spread through 250 Pages and an in-depth TOC on "Xenotransplantation Market"
The global xenotransplantation
market segmentation is based on animal type, xeno product, organs, end user,
competitive landscape, and regional distribution. Based on animal type, the
market is further divided between pig, baboon, rabbit, and others (cow, chimpanzee).
Pig segment dominated the market in 2021
with an overall market share of around 45.30%. Pigs are preferred because they mature quickly, have
large litters, and have organs in both infancy and adulthood that are
comparable in size and function to human organs. In microbiologically
controlled environments, they can also be bred to high health standards.
Based on organ, the
market can be divided into kidney, heart, liver, cornea, and others (pancreas). When
compared to a lifetime on dialysis, a kidney transplant is frequently the
treatment of choice for many who suffer from kidney failure. A kidney
transplant can help you feel better and live longer if you have chronic kidney
disease or end-stage renal disease.
Some of the major companies
operating in the global xenotransplantation market include:
- Novartis AG
- Accord Healthcare
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd.
- Terumo Medical Corporation
- Transonic
- Astellas Pharma, Inc.
- Preservation Solutions, Inc.
- Bio Med Pvt. Ltd.
- TransMedic, Pte. Ltd.
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
Humans'
increased life expectancy has resulted in an increase in the number of patients
suffering from chronic diseases and end-stage organ failure. Transplantation is
an effective treatment for end-stage organ failure; however, an imbalance in
organ supply and demand for human organs is a bottleneck for clinical
transplantation. As a result, xenotransplantation may be a promising
alternative approach to bridging the supply-demand gap for organs, tissues, and
cells; however, immunological barriers are limiting factors in clinical
xenotransplantation. “Clinical xenotransplantation has become more viable due
to advances in gene editing tools and immunosuppressive therapy, as well as
longer xenograft survival time in pig-to-non-human primate models.; thus, there
will be a positive impact on the xenotransplantation market, and the market is
expected to prosper during the forecast period,” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based global management
consulting firm.
“Xenotransplantation
Market- Global
Industry Size, Share, Trends, Competition, Opportunities and Forecast, 2021-2031
By Animal
Type (Pigs, Rabbit, Baboon, Others) By Xeno Product (Organs, Tissues, Cells) By
Organs (Kidney, Heart, Liver, Cornea, and Others) By End User (Transplant
Center, Hospitals and Others) By Region, Competition, Forecast &
Opportunities, 2031”, has evaluated the future growth potential of global xenotransplantation
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in global xenotransplantation market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com